Outlook Therapeutics, Inc. (OTLK)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Sep 30
In fiscal 2025, Outlook Therapeutics, Inc. reported revenue of $1.41M. The company ran a net loss, with a net margin of -4416.2% and a gross margin of 4.0%. It held $18.58M in total assets against $50.77M in total liabilities.
Key ratios (FY2025)
4.0%
Gross margin
-4744.3%
Operating margin
-4416.2%
Net margin
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.41M | — | — | — | — | — | — | — | — | — |
| Cost of Revenue | $1.36M | — | — | — | — | — | — | — | — | — |
| Gross Profit | $57.2K | — | — | — | — | — | — | — | — | — |
| Operating Income | -$67.06M | -$71.70M | -$53.13M | -$63.07M | -$51.73M | -$36.84M | -$36.30M | -$29.64M | -$35.88M | -$51.35M |
| Net Income | -$62.42M | -$75.37M | -$58.98M | -$66.05M | -$53.16M | -$35.24M | -$34.52M | -$30.09M | -$38.85M | -$53.30M |
| EPS (Diluted) | $-1.79 | $-4.06 | $-4.72 | $-0.31 | $-0.35 | $-0.67 | — | $-1.22 | $-1.80 | $-3.67 |
| Total Assets | $18.58M | $28.82M | $32.30M | $28.53M | $22.81M | $19.73M | $17.13M | $22.28M | $20.73M | $25.41M |
| Total Liabilities | $50.77M | $101.90M | $46.74M | $19.79M | $18.20M | $16.91M | $27.90M | $43.09M | $51.46M | $30.58M |
| Shareholders' Equity | -$32.19M | -$73.08M | -$14.44M | $8.74M | $4.61M | $2.83M | -$16.13M | -$25.54M | -$33.65M | -$5.17M |
| Cash & Equivalents | $8.08M | $14.93M | $23.39M | $17.40M | $14.48M | $12.54M | $8.02M | $1.72M | $3.19M | $2.35M |
| Operating Cash Flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | -$54.25M | -$31.79M | -$32.29M | -$33.04M | -$15.51M | — |
| Capital Expenditures | — | — | — | — | — | — | $437.3K | $2.78M | $292.1K | $1.10M |
| Shares Outstanding | 53.89M | 23.91M | 13.01M | 227.31M | 176.46M | 127.18M | 28.61M | 9.03M | 24.93M | 22.80M |